期刊文献+

Graves眼病放射治疗121例临床观察 被引量:1

Radiotherapy in Graves' orbitopathy--clinical analysis of 121 cases
下载PDF
导出
摘要 目的分析Graves眼病放射治疗后的疗效及影响预后的因素。方法1990年~2005年121例Graves眼病患者,其中男性75例,女性46例,年龄17~68岁,中位年龄42.2岁。双眼发病者为92例,单眼发病者为29例。病程中位时间14.1个月。既往病史:糖尿病患者11例,高血压患者21例、有吸烟史的患者69例。患者接受球后放射治疗,常规分次照射,总剂量2000cGy,随访期为6个月~15年。结果照射后分别有32.2%、46.3%的患者病情明显改善和部分改善,15.7%的患者病情稳定,5.8%的患者病情进展。有软组织及角膜受累的病例放疗后症状改善最为明显(P<0.05)。结论放射治疗可有效地控制Graves眼病病情进展,并取得较好疗效,使临床症状得到改善。 Objective To study the effect of radiotherapy in Graves" orbitopathy and the factors influencing prognosis. Methods During 1990 to 2005,121 patients with progressive Graves" orbitopathy were enrolled in the study, male 75 patients and female 46 patients,aged 17 to 68 years,median age 42.2 years. Ninty-two patients with binocular Graves" orbitopathy and 29 patients with ocellus Graves" orbitopathy were enrolled. Median duration of illness was 14.1 months. All patients were received bilateral orbital irradiation 2 000 cGy in 2 weeks. The patients were following-up between 6 months and 15 years. Their response to radiation was analyzed. Results The results in patients after radiotherapy were:significant improved 32.2 % (9/121),partial improved 46.3 %(56/121 ) ,stable symptoms 15.7 %( 19/121 ) ,symptoms progressed 5.8 %(7/121 ). Most significant resuhs(P 〈 0.05 ) were found in patients involved with soft tissue and cornea. Conclusion Radiotherapy could effective control the symptoms of Graves" orbitopathy result in better therapeutic effect and clinical manifestation improvement.
出处 《生物医学工程与临床》 CAS 2007年第3期210-214,共5页 Biomedical Engineering and Clinical Medicine
关键词 GRAVES眼病 放射治疗 三维适形放疗 Graves' orbitopathy radiotherapy three-dimensional conformal radiotherapy
  • 相关文献

参考文献10

  • 1Petersen LA,Kriss JP,McDougall IR,et al.Prognostic factors in the radiotherapy of Graves'ophthalmopathy[J].Int J Radiat Oncol Biol,1990,19(2):259-264.
  • 2Olivotto IA,Ludgate CM,Allen LH,et al.Supervoltage radiotherapy for Graves'ophthalmopathy:CCABC technique and results[J].Int J Radiat Biol Phys,1985,1 1(12):2085-2090.
  • 3Marcocci C,Balmena L,Panicucci M,et al.Orbital cobah irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy:a comparative study[J].Clin Endocrinol(Oxf),1987,27(1):33-42.
  • 4Prummel MF,Mourits MP,Blank L,et al.Randomized doubleblind trial of prednisone versus radiotherapy in Graves'ophthalmopathy[J].Lancet,1993,342(8877):949-954.
  • 5Mourits MP,van kempen-Harteveld ML,Garcia MB,et al.Radiotherapy for Graves'orbitopathy:randomised placebo-controlled study[1].Lancet,2000,355(9214):1505-1509.
  • 6Prummel MF,Terwee CB,Gerding MN,et al.A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy[J].J Clin Endocfinol Metab,2004,89(1):15-20.
  • 7Gorman CA,Garrity JA,Fatourechi V,et al.Aprospective,randomized,double-blind,placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy[J].Ophthalmology,2001,108:1523-1534.
  • 8Banalena L,Marcocci C,Pinchera A,et al.Orbital Radiotherapy for Graves' Ophthalmopathy[J].J Clin Endocrinol Metab,2004,89(1):13-14.
  • 9Bartalena L.Orbital radiation therapy and Graves' ophthalmopathy[J].Ophthalmology,2003,110(3):452-453.
  • 10Kahaly GJ,Rosler HP,Pitz S,etal.Low-versus high-dose radiotherapy for Graves' ophthalmopathy:a randomized,single blind trial[J].J Clin Endocrinol Metab,2000,85(1):102-108.

同被引文献16

  • 1Viani GA,Boin AC,De Fendi LI. Radiation therapy for Graves'ophthalmopathy:a systematic review and meta-analysis of randomized controlled trials[J].{H}Arquivos Brasileiros de Oftalmologia,2012,(05):324-332.
  • 2Kouloulias V,Kouvaris J,Zygogianni A. Efficacy and toxicity of radiotherapy for Graves'ophthalmopathy:the University of Athens experience[J].Head Neck Oncol,2013,(02):12.
  • 3Tanda ML,Bartalena L. Efficacy and safety of orbital radiotherapy for graves'orbitopathy[J].{H}Journal of Clinical Endocrinology and Metabolism,2012,(11):3857-3865.
  • 4Terwee CB,Gerding MN,Dekker FW. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy:the GO-QOL[J].{H}British Journal of Ophthalmology,1998,(07):773-779.
  • 5Terwee C,Wakelkamp I,Tan S. Long-term effects of Graves'ophthalmopathy on health-related quality of life[J].{H}European Journal of Endocrinology,2002,(06):751-757.
  • 6Terwee CB,Dekker FW,Mourits MP. Interpretation and validity of changes in scores on the Graves'ophthalmopathy quality of life questionnaire(GO-QOL)after different treatments[J].{H}Clinical Endocrinology(Oxford),2001,(03):391-398.
  • 7Park JJ,Sullivan TJ,Mortimer RH. Assessing quality of life in Australian patients with Graves'ophthalmopathy[J].{H}British Journal of Ophthalmology,2004,(01):75-78.
  • 8Lee H,Roh HS,Yoon JS. Assessment of quality of life and depression in Korean patients with Graves'ophthalmopathy[J].{H}Korean Journal of Ophthalmology,2010,(02):65-72.
  • 9Wiersinga WM. Quality of life in Graves'ophth-almopathy[J].{H}Best Practice and Research Clinical Endocrinology and Metablism,2012,(03):359-370.
  • 10Choi YJ,Lim HT,Lee SJ. Assessing Graves'ophthalmopathy-specific quality of life in Korean patients[J].Eye(Lond),2012,(04):544-551.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部